Organovo is a seed-stage regenerative medicine company that applies proprietary organ printing technology to solve critical problems in transplant medicine, cardiovascular medicine, tissue repair, and medical research. 

Organovo aims to solve complex medical problems with one overarching goal: to benefit the health and lives of our patients.

Regenerative medicine is among the most exciting and promising new technologies in the field of bioscience.  Organovo works with leading academic, scientific, clinical and regulatory experts to develop our technologies.  Our strategy and innovations are shaped by a Scientific Advisory Board comprised of top researchers and clinicians, and our leadership team is focused on making sure that the breakthrough technologies we create lead to breakthrough products for patients.  At Organovo, we promise to turn great science into great solutions.